VideoHIV23rd European Meeting on HIV & Hepatitis 2025Abstract #7 Resistance Analysis of Long-Acting Lenacapavir in Heavily Treatment-Experienced People with HIV After 3 Years of Lenacapavir Treatment - Nicolas MargotView Video
SlidesetHIV23rd European Meeting on HIV & Hepatitis 2025Abstract #7 Resistance Analysis of Long-Acting Lenacapavir in Heavily Treatment-Experienced People with HIV After 3 Years of Lenacapavir Treatment - Nicolas MargotView Slideset
VideoHIV23rd European Meeting on HIV & Hepatitis 2025Abstract #6 Lenacapavir Resistance Profile in Heavily Treatment-Experienced People in the PRESTIGIO Registry - Maria Mercedes SantoroView Video
SlidesetHIV23rd European Meeting on HIV & Hepatitis 2025Abstract #6 Lenacapavir Resistance Profile in Heavily Treatment-Experienced People in the PRESTIGIO Registry - Maria Mercedes SantoroView Slideset
SlidesetHIV23rd European Meeting on HIV & Hepatitis 2025Abstract #5 A French National Real-World Survey of People with Multi-Resistant HIV-1 Viruses Treated with an Antiretroviral Regimen Including Fostemsavir or Ibalizumab - Charlotte CharpentierView Slideset
VideoHIV23rd European Meeting on HIV & Hepatitis 2025Abstract #4 WG-am: A Novel Antiviral Dipeptide from Elite Controllers as a Promising Vaginal Microbicide for HIV Prevention - Rafael Ceña DiezView Video
SlidesetHIV23rd European Meeting on HIV & Hepatitis 2025Abstract #4 WG-am: A Novel Antiviral Dipeptide from Elite Controllers as a Promising Vaginal Microbicide for HIV Prevention - Rafael Ceña DiezView Slideset
VideoHIV23rd European Meeting on HIV & Hepatitis 2025Abstract #3 Unveiling Novel Microbiome Signatures for Natural Virological Control in HIV-1 Elite Controllers - Xiangning BaiView Video
SlidesetHIV23rd European Meeting on HIV & Hepatitis 2025Abstract #3 Unveiling Novel Microbiome Signatures for Natural Virological Control in HIV-1 Elite Controllers - Xiangning BaiView Slideset
VideoHIV23rd European Meeting on HIV & Hepatitis 2025Abstract #2 In Addition to Their Ability to Induce Resistance to Antiretrovirals, Integrase Inhibitors and Lenacapavir Resistance Mutations Enable HIV-1 to Evade Recognition by the Innate Immune System - Elisa TeyssouView Video
SlidesetHIV23rd European Meeting on HIV & Hepatitis 2025Abstract #2 In Addition to Their Ability to Induce Resistance to Antiretrovirals, Integrase Inhibitors and Lenacapavir Resistance Mutations Enable HIV-1 to Evade Recognition by the Innate Immune System - Elisa TeyssouView Slideset
VideoHIV23rd European Meeting on HIV & Hepatitis 2025Abstract #1 Comparable Dynamics of Cell-Associated HIV-RNA, Total and Intact Proviral HIV-1 DNA in Virologically Suppressed People with HIV Switching to 2DR or Continuing 3DR Over an 18-Month Follow-Up - Lia FiaschiView Video
